Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Stifel Canada increased their Q4 2024 earnings per share estimates for Cipher Pharmaceuticals in a research report issued on Tuesday, October 22nd. Stifel Canada analyst J. Keywood now expects that the company will post earnings per share of $0.23 for the quarter, up from their prior estimate of $0.22. Stifel Canada has a "Strong-Buy" rating on the stock. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.65 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals' FY2025 earnings at $1.06 EPS.
Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last posted its earnings results on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of C$0.15 by C$0.01. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The firm had revenue of C$7.26 million during the quarter, compared to analyst estimates of C$7.52 million.
Several other analysts also recently weighed in on CPH. Stifel Nicolaus lifted their target price on Cipher Pharmaceuticals from C$17.00 to C$19.00 in a research note on Thursday. Leede Financial cut shares of Cipher Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 13th.
View Our Latest Stock Report on Cipher Pharmaceuticals
Cipher Pharmaceuticals Stock Performance
Shares of TSE CPH traded down C$0.33 during midday trading on Thursday, hitting C$16.15. 16,650 shares of the company's stock were exchanged, compared to its average volume of 46,755. Cipher Pharmaceuticals has a twelve month low of C$4.30 and a twelve month high of C$19.69. The firm has a market cap of C$413.28 million, a P/E ratio of 13.06 and a beta of 1.20. The stock's 50 day moving average price is C$16.35 and its 200-day moving average price is C$11.71. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Further Reading
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
